- Global Pharma News & Resources

Highly Fragmented Regenerative Medicine Market Allows Smaller Companies to Shine, States Fairfield Market Research

As the incident rate of chronic diseases becomes a matter of global concern, regenerative medicine has gained popularity as a multi-faceted line of treatment. Regenerative medicine is useful in wound healing to disease control and is increasingly being preferred to conventional medicine. The emergence of nanotechnology and stem cell technology are anticipated to be the biggest drivers in the regenerative medicine market during the forecast period.

Get PDF Sample Copy of this Report (Including Full TOC, List of Tables & Figures) :

Oncology Holds Dominant Position in the Regenerative Medicine Market

Hundreds of stem cell and gene therapy products are in the stage of industrial development, while others are being developed by research institutes. Regenerative medicines require approval from regulatory authorities such as the US Food & Drug Administration, Japan’s Pharmaceuticals and Medical Devices Agency, and European Medicines Agency before they can be sold in the regenerative medicine market. There are thousands of clinical trials currently underway at different stages with oncology demonstrating the greatest potential as it accounts for more than half the studies in the regenerative medicine market.

Lack of Long-term Data Results in Prohibitive Prices in Regenerative Medicine Market

Cell and gene therapies are prohibitively expensive, making it virtually impossible for conventional reimbursement to be the panacea needed. For advanced lymphoma, the treatment cost in developed countries is hundreds of thousands of dollars while the cost of Zolgensma to treat paediatric spinal muscular atrophy is more than a million dollars per patient. Furthermore, a lack of contradictory views among marketers, patients, and healthcare providers due to a dearth of long-term follow-up data makes it unlikely that prices in the regenerative medicine market will drop anytime soon.

M&A Activity Continues in the Regenerative Medicine Market, COVID-19 Notwithstanding

Even though COVID-19 caused massive disruptions to the global economy, the regenerative medicine market was remarkably resilient in 2020. In the first half of 2020, more investment was pumped into the regenerative medicine market than in the entire 2019. Robust funding from the private sector and governments is expected to raise the profile of the regenerative medicine market. Financing is easily accessible through partnerships and venture capital, and mergers & acquisitions are of critical importance to middle cap pharma companies in the gene therapy segment.

In Order to place the Purchase Query Click Here:

North America Has Cash-rich Companies Able to Invest in Regenerative Medicine Market

There are more than 1000 small and medium therapeutic companies actively involved in the regenerative medicine market with North America home to more than half and Europe a quarter. A noteworthy fact is that less than a fifth of stem-cell therapies currently under development are by the big pharma companies. These companies find in-licensing to be a useful strategy in the integration of technologies that are relatively advanced. Such a risk-adverse approach is necessitated by a desire to invest in only proven technologies because of the high costs involved.

Some companies profiled in the report on the regenerative medicine market include BIOTECH, Anges, Avexis, Dendreon, Avita Medical, Anterogen, Bellicum Pharma, BioCardia, BioLife Solutions, BioMarin, BioStage, bluebird bio, Inc., Bone Therapeutics, BrainStorm Cell Therapeutics, Cabaletta Bio, Caladrius Bio, Capricor Therapeutics, Cardinal Health, Celgene (BMS), Cellect Bio, CBMG, CombiGene, CRISPR Therapeutics, Cryoport Systems, CSL Limited, Cynata Therapeutics, Editas Medicine, Fate Therapeutics, Fibrocell Science, Flexion Tx, and Fresenius Kabi.

Browse Our Latest Reports: 

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

Highly Fragmented Regenerative Medicine Market Allows Smaller Companies to Shine, States Fairfield Market Research

Editor Details

Last Updated: 12-Jul-2021